31st Jul 2020 11:06
Oxford Biomedica PLC - gene and cell therapy company with headquarters in Oxford - Inks three-year clinical supply agreement with Axovant Gene Therapies Ltd, building on previous 2019 worldwide license agreement for Parkinson's disease gene therapy program. The programme is now called AXO-Lenti-PD. Oxford Biomedica will manufacture good manufacturing practice batches for Axovant, supporting clinical development of clinical-stage gene therapy product AXO-Lenti-PD. AXO-Lenti-PD is intended to treat moderate to severe Parkinson's disease and is based on Oxford Biomedica's LentiVector platform. A phase 2 trial of AXO-Lenti-PD is ongoing and is being conducted by Axovant. Data is due in the fourth quarter of 2020. Oxford Biomedica "expects to manufacture AXO-Lenti-PD in its commercial-scale GMP manufacturing facilities including Oxbox in the UK, and additionally in other [Oxford Biomedica] GMP facilities as required to ensure security of supply."
Current stock price: 819.77 pence
Year-to-date change: up 22%
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica